Ivermectin Has Topical Anti-Inflammatory Properties

Share this content:
Ivermectin Has Topical Anti-Inflammatory Properties
Ivermectin Has Topical Anti-Inflammatory Properties

MONDAY, Jan. 9, 2017 (HealthDay News) -- Ivermectin (IVM) has anti-inflammatory properties that could be beneficial in treatment of T-cell mediated skin inflammatory diseases, according to an experimental study published online Jan. 4 in Allergy.

Erwan Ventre, Ph.D., from the Université de Lyon in France, and colleagues examined the activity of IVM in a murine model of atopic dermatitis induced by repeated exposure to Dermatophagoides farinae and in cellular immunology assays.

The researchers found that topical IVM correlated with improvement in allergic skin inflammation, with reduction of the priming and activation of allergen-specific T cells and the production of inflammatory cytokines. IVM had no major effect on dendritic cell functions in vivo and in vitro, but following polyclonal and antigen-specific stimulation, IVM did impair T-cell activation, proliferation, and cytokine production.

"Altogether, our results show that IVM is endowed with topical anti-inflammatory properties that could have important applications for the treatment of T-cell mediated skin inflammatory diseases," the authors write.

Several authors were employed by Galderma, which manufactures ivermectin and funded the study.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

60 Percent of Adults Report Adverse Childhood Experiences

>60 Percent of Adults Report Adverse Childhood Experiences

Higher ACE exposures for black, Hispanic, multiracial individuals, those with below high school education

Few Yogurt Products Qualify As Low-Sugar

Few Yogurt Products Qualify As Low-Sugar

Only two of 101 children's yogurt and fromage frais products had ≤5 g sugar/100 g of product

Allopurinol Dose Escalation for Gout Doesn't Improve Mortality

Allopurinol Dose Escalation for Gout Doesn't Improve Mortality

Linked to small increase in mortality; at 2 years, 31 percent of dose escalators achieved serum urate goal

is free, fast, and customized just for you!




Already a member?

Sign In Now »